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Methods Summary and Conclusion
References
Objectives: Doxorubicin (DOX) is an effective chemotherapy drug used to treat breast cancer, 
but is limited by detrimental side effects such as cardiotoxicity and skeletal muscle atrophy. 
Supplementation with creatine has been shown to protect cardiac and skeletal muscle cells 
from the cytotoxic effects of DOX. However, a concern with dietary creatine supplementation in  
cancer patients is the possible protection of  cancer cells from therapeutic DOX toxicity. Thus, 
we investigated the effects of in vitro creatine supplementation on proliferation and survival of 
DOX-treated MAT-BIII, rat mammary carcinoma cells. Methods: MATB-III cells were seeded  in 
triplicate at 15,000 cells/well in a 96-well microplate for an eight day incubation in one of six 
treatments: no treatment, 5 nM DOX, 2mM creatine, 2mM creatine + 5 nM DOX, 20mM 
creatine, 20mM creatine + 5 nM DOX. Media and treatments were refreshed every 48 hours. An 
MTT assay was run on day 8 to assess remaining cell number in each well. The results represent 
an average from three time separated experiments, with  differences between treatments 
identified using a two-way ANOVA (IBM SPSS 27) and a significance threshold of 0.05. Results: 
As expected, the number of MAT-BIII  cells was significantly reduced (P < .001) after  DOX 
treatment, consistent with impaired  proliferation or cytotoxicity. Neither low nor high-dose 
creatine exposure altered the number of cells, or the suppressive effects of DOX as no 
interaction  between creatine and DOX was identified (P > 0.05). Conclusion: DOX decreased 
proliferation of MAT-BIII mammary carcinoma cells, indicating this cell line is sensitive to the 
effects of this chemotherapy drug. There was no indication that creatine  influenced 
proliferation or DOX sensitivity of the mammary carcinoma cells.  The absence of an  effect in 
this experiment suggests that creatine could be supplemented to alleviate the adverse side 
effects of DOX  treatment in human breast cancer patients. Future research aims to elucidate 
further the possible interactions between DOX and creatine in cancer cell metabolism.
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Figure 2: MAT-BIII Doxorubicin (Dox) and Creatine Incubation Pictures
Creatine monohydrate is a popular dietary supplement that has traditionally been 
used to enhance athletic performance. Supplementing the diet with creatine 
increases lean body mass, reduces muscular fatigue, and improves sprint 
performance (1, 2). More recently, creatine has gained attention as a possible clinical 
supplement in several disorders including cardiovascular disease, muscular dystrophy, 
and cancer (3-5). The role of creatine in cancer is particularly interesting because of 
its potential to attenuate skeletal muscle wasting and the cardiotoxic effects of 
chemotherapy treatments.
Creatine supplementation research has primarily focused on the bioenergetic 
benefit of increased phosphocreatine concentrations promoting enhanced ATP 
synthesis; however, creatine can also help regulate glycolysis, decrease cytosolic 
acidosis, or scavenge reactive oxygen species (6, 7). These protective properties 
support the potential use of creatine as an approach to mitigate the negative side 
effects commonly observed in cancer patients undergoing chemotherapy treatments. 
Doxorubicin (DOX) is a commonly used chemotherapy agent, but its use is limited by 
its toxic effects on cardiac and skeletal muscle. Creatine supplementation has been 
shown to attenuate DOX-induced skeletal muscle dysfunction and improve cardiac cell 
survival (8, 9); however, the effect of creatine supplementation on cancer cell 
proliferation and sensitivity to DOX is still unclear.
Cancer progression is known to alter the phosphocreatine system (10). Therefore, 
the interaction between cancer and the phosphocreatine system is a potential 
concern for creatine supplementation during chemotherapy treatment. Interestingly, 
in-vivo studies have demonstrated an ability of creatine supplementation to decrease 
tumor growth (11, 12). Alternative in-vitro research, however, indicates that 
overexpression of the ubiquitin mitochondrial creatine kinase enzyme enhances 
cellular proliferation and inhibits apoptosis in mouse and human breast cancers (13, 
14). The phosphocreatine system has also been shown to significantly impact the 
sensitivity of cancer cells to DOX. For example, decreasing the expression of cytosolic 
ubiquitin creatine kinase in leukemia and ovarian cancer cell lines displayed an 
increased sensitivity to DOX (15, 16).  The current project aims to further explore the 
effect of creatine supplementation on cell proliferation and DOX sensitivity in 
mammary carcinoma cells.
Mammary carcinoma cells (MAT-BIII) were grown in minimum essential media 
supplemented with 10% fetal bovine essence (FBE) and 1% penicillin/streptomycin. MAT-BIII 
cells were plated in triplicate at 15,000 cells/well in a 96 well microplate for an eight day
incubation in one of six treatments: No Treatment (Control), 5 nM DOX, 2mM creatine, 2mM 
creatine + 5 nM DOX, 20mM creatine, 20mM creatine + 5 nM DOX. To ensure adequate 
substrate concentrations, the treatment media was refreshed every 48 hours.
On day eight of the incubation, an MTT assay was run to examine cellular proliferation and 
analyzed using a spectrophotometer at 595 nm. Cell images were taken on the final incubation 
day as a visual verification of the MTT assay. The results are a summary of the three, time 
separated incubations. The main effects and interaction between DOX and creatine were 
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Figure 1. MTT assay. When compared to 
Control, the MTT assay of MAT-BIII cells 
treated with 5nM DOX revealed a significant 
main effect of DOX, consistent with impaired 
proliferation (P < .001). MAT-BIII cells 
incubated in low creatine (2mM) and high 
creatine (20mM) had no significant main 
effect on proliferation (P = 0.771). 
The cells treated with 5nM DOX and 
creatine exhibited no interaction between 
creatine and DOX (P = 0.974).
Figure 2. Cell images of each treatment 
on the final day (day 8) of the incubation. 
Provided as a visual verification of the MTT 
assay. 
Figure 1: MAT-BIII Doxorubicin (Dox) and Creatine MTT Assay
Table 1: MAT-BIII Incubation Groups
The 5nM concentration of DOX was observed to be cytotoxic to MAT-BIII 
cells over the eight day incubation used in this study. The cytotoxicity was 
demonstrated with an MTT assay (Figure 1) and verified with cell 
visualization (Figure 2). This low concentration of DOX (5nM) required an 
extended period of time (8 days) to decrease cell number significantly and 
was selected to give creatine sufficient time to potentially reduce the 
cytotoxic effects of DOX.
Neither the low physiological dose of creatine (2mM) nor the high dose of 
creatine (20mM) had a significant main effect on the mammary carcinoma 
proliferation. This supports the hypothesis that creatine would not affect 
mammary carcinoma proliferation in-vitro.
A secondary outcome was to investigate the effect of creatine on MAT-BIII 
cell sensitivity to DOX. Creatine did not have a significant interaction with 
DOX cytotoxicity. Neither the 2mM nor the 20mM creatine concentration 
had a significant effect on DOX in mammary carcinoma cells.
This research suggests that the use of dietary creatine in breast cancer 
patients receiving DOX will not impact the anticancer effects of DOX. Future 
research is needed to investigate the effect of creatine supplementation and 
DOX sensitivity on a variety of cancer cells.
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